Premature ejaculation: Treatment update

International Journal of STD and AIDS

Volumn 21, Issue 2, 2010, Pages 77-81

  McCarty, E J ^a   Dinsmore, W W ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Dapoxetine; PDE 5 inhibitor; Premature ejaculation; Selective serotonin re uptake inhibitor; TEMPE; Tramadol

Indexed keywords

5 CYANO 3 [2 (DIMETHYLAMINOMETHYL)CYCLOPROPYL]INDOLE; ALFUZOSIN; ALPROSTADIL PLUS DYCLONINE; ANESTHETIC AGENT; CITALOPRAM; CLOMIPRAMINE; DAPOXETINE; EMLA; FLUOXETINE; HERBACEOUS AGENT; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEVERANCE SECRET CREAM; SILDENAFIL; TADALAFIL; TERAZOSIN; TRAMADOL; UNCLASSIFIED DRUG;

AGITATION; ANTICHOLINERGIC SYNDROME; ANXIETY; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DISTRESS SYNDROME; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEADACHE; HOT FLUSH; HUMAN; HYPESTHESIA; INSOMNIA; LIBIDO DISORDER; LOW DRUG DOSE; MORBIDITY; NAUSEA; NOSE CONGESTION; PATIENT SATISFACTION; PREMATURE EJACULATION; PRIORITY JOURNAL; REVIEW; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SEXUALITY; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANESTHETICS, COMBINED; ANESTHETICS, LOCAL; BENZYLAMINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EJACULATION; ENZYME INHIBITORS; HUMANS; LIDOCAINE; MALE; NAPHTHALENES; PRILOCAINE; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 75449119313     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009434     Document Type: Review

References (59)

1. Rowland DL, Perelman MA, Althof SE, et al. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med 2004;1:225-32
2. Rosen RC. The premature ejaculation prevalence and attitudes (PEPA) survey: a multi-national survey. J Sex Med 2004;1(Suppl. 1):57-8
3. Spector IP, Carey M. Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav 1990;19:389-408
4. McMahon CG, Althof S, Waldinger MD, et al. An evidence-based definition of premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 2008;102:338-50
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Text Revision. Washington, DC: American Psychiatric Association, 2000
6. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Proposal for a de.nition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med 2005;2:498-507
7. Althof S. The psychology of premature ejaculation: therapies and consequences. J Sex Med 2006;3(Suppl. 4):324-31
8. Donatucci C. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med 2006;3(Suppl. 4):303-8
9. Waldinger M. The neurobiological approach to premature ejaculation. J Urol 2002;168:2359-67
10. Waldinger M, Rietschel M, Nothen M, et al. Familial occurrence of primary premature ejaculation. Psychiatr Genet 1998;8:37-40
11. Jern P, Santtila P, Johansson A, et al. Evidence for a genetic etiology to ejaculatory dysfunction. Int J Impot Res 2009;21:62-7
12. Janssen PK, Bakker SC, Rethelyi J, et al. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculatory latency time in Dutch men with lifelong premature ejaculation. J Sex Med 2009;6:276-84
13. Ozbek E, Tasci AI, Tugcu V, et al. Possible association of the 5-HTTLPR serotonin transporter promoter gene polymorphism with premature ejaculation in a Turkish population. Asian J Androl 2009;11:351-5
14. Safarinejad MR. Polymorphisms of the serotonin transporter gene and their relation to premature ejaculation in individuals from Iran. J Urol 2009; 181:2656-61
15. Safarinejad MR. Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation. BJU Int 2009 [Epub ahead of print]
16. Semans JH. Premature ejaculation: a new approach. South Med J 1956;49:353-8
17. Masters WH, Johnson VE. Human Sexual Inadequacy. Boston: Little Brown, 1970
18. Melnik T, Glina S, Rodrigues OM Jr. Psychological intervention for premature ejaculation. Nat Rev Urol 2009;6:501-8
19. Schapiro B. Premature ejaculation: a review of 1130 cases. J Urol 1943;3:374-9
20. Xin ZC, Chung WS, Choi YD, Seong DH, Choi YJ, Choi HK. Penile sensitivity in patients with primary premature ejaculation. J Urol 1996;156:979-81
21. Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia 2002;34:356-9
22. Bustato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomised, placebo-controlled study. BJU Int 2004;93:1018-21
23. Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2007;99:369-75
24. Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int 2009;103:940-9
25. Xin ZC, Choi YD, Lee SH, Choi HK. Efficacy of a topical agent SS-cream in the treatment of premature ejaculation: preliminary clinical studies. Yonsei Med J 1997;38:91-5
26. Choi HK, Xin ZC, Choi YD, et al. Safety and ef.cacy study with various doses of SS-cream in 1 patients with premature ejaculation in a double-blind, randomised, placebo controlled clinical trial. Int J Impot Res 1999;11:261-4
27. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology 2000;55:257-61
28. Gittleman MC, Mo J, Lu M. Synergistic effect of meatal application of dyclonine/alprostadil cream for the treatment of early ejaculation in a double-blind crossover study. J Sex Med 2006;3(Suppl. 3):176
29. Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacological management of premature ejaculation. J Urol 2004;172:290-4
30. Montejo AL, Llora G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicentre study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62:10-21
31. Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systemic review and meta-analysis. Int J Impot Res 2004b;16:369-81
32. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255-61
33. Lader M. Pharmacotherapy of mood disorders and treatment discontinuation. Drugs 2007;67:1657-63
34. Waldinger MD, Schweitzer DH, Olivier B. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med 2005b;2:121-31
35. Modi NB, Dresser MJ, Simon M, et al. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006;46:301-9
36. Pryor JL, Althof S, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006;368:939- 47
37. McMahon C, Park NC, Zhao Y, et al. Treatment of premature ejaculation (PE) in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. Oral Presentation at: 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine, Jeju, Korea, 6-10 October 2007
38. Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomised, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009;55:957-68
39. Kaufman JM, Rosen RC, Mudumbi RV. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2009;103:651-8
40. Shabsigh R, Pryor JL, Tesfaye F. Dapoxetine for the treatment of premature ejaculation: low incidence of sexual side effects. J Sex Med 2007;4(Suppl. 2):118
41. Guiliano F, Levine SB, Buvat J, et al. Lack of withdrawal syndrome or effects on anxiety with dapoxetine for the treatment of premature ejaculation (PE): results from 2 phase III trials (abstract). Eur Urol Suppl 2008;7:187
42. Modi NB, Dresser M, Desai D. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol 2007;47:315-22
43. Dresser MJ, Desai D, Gidwani S. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 2006;18:104-10
44. Waldinger MD, Zwinderman A, Olivier B, et al. The majority of men with lifelong premature ejaculation prefer daily drug treatment: An observational study in a consecutive group of Dutch men. J Sex Med 2007;4:1028-37
45. Salonia A, Rocchini L, Sacca A, et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Urol 2009;182:1101-7
46. Waldinger MD, Schweitzer DH. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med 2008;5:966-97
47. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. J Clin Psychopharmacol 2006;26:27-31
48. Salem EA, Wilson SK, Bissada NK, et al. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med 2008;5:188-93
49. Abdel-Hamid IA, El-Naggat EA, El-Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001;13:41-5
50. Salonia A, Maga T, Colombo R, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 2002;168:2468-9
51. McMahon CG, Stuckey BG, Anderson M, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005;2:368-75
52. McMahon CG, McMahon CN, Leow LJ. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006;98:259-72
53. Girgis SM, El-Haggar S, El-Hermouzy S. A double blind trial of clomipramine in premature ejaculation. Andrologia 1982;14:364-8
54. Segraves RT, Saran A, Segraves A, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marit Ther 1993;19:198-200
55. Haensel SM, Rowland DR, Kallan KT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol 1996;156:1310- 5
56. Kim SC, Seo KK. Ef.cacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998;159:425-7
57. Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomised, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004;46:510-5
58. Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol 1995;28:126-30
59. Base MM, Yilmaz E, Ferhat M, et al. Terazocin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol 2005;37:773-7 (Accepted 28 September 2009)